No shortcuts to SARS-CoV-2 antivirals
Are many drug repurposers pursuing artifacts? When the COVID-19 pandemic hit, there was massive investment into the discovery of new treatments. Given the urgent need, repurposing of approved or clinically pretested drugs appeared especially attractive because that strategy promised fast initiation...
Gespeichert in:
| Veröffentlicht in: | Science (American Association for the Advancement of Science) 2021-07, Vol.373 (6554), p.488-489 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 489 |
|---|---|
| container_issue | 6554 |
| container_start_page | 488 |
| container_title | Science (American Association for the Advancement of Science) |
| container_volume | 373 |
| creator | Edwards, Aled Hartung, Ingo V. |
| description | Are many drug repurposers pursuing artifacts?
When the COVID-19 pandemic hit, there was massive investment into the discovery of new treatments. Given the urgent need, repurposing of approved or clinically pretested drugs appeared especially attractive because that strategy promised fast initiation of antiviral clinical studies. On page 541 of this issue, the study by Tummino
et al.
(
1
) raises concerns that many drug candidates that showed antiviral activity in hypothesis-free cellular screens and were then repurposed to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections may be scientific dead ends. Their study is a warning that even amid the pressure of a pandemic, scientific diligence is still essential. |
| doi_str_mv | 10.1126/science.abj9488 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2557221811</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2557221811</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-c52ce03297b39660ad9087e63f6eb14c51d5dcad1fbf58dc1078f74d62d6ab583</originalsourceid><addsrcrecordid>eNpdkEtLAzEYRYMoWKtrtwMiuEmbL5m8lqX4gqJg1W3IJBmc0k5qMiP4753SWbm6i3u4XA5C10BmAFTMs2tC68LMVhtdKnWCJkA0x5oSdoomhDCBFZH8HF3kvCFk6DSboNuXWOSvmDrXd7noYrFevK3xMn5iWti2a36aZLf5Ep3VQ4SrMafo4-H-ffmEV6-Pz8vFCjsmocOOUxcIo1pWTAtBrNdEySBYLUIFpePguXfWQ13VXHkHRKpall5QL2zFFZuiu-PuPsXvPuTO7JrswnZr2xD7bCjnklJQAAN68w_dxD61w7sDJUohQNOBmh8pl2LOKdRmn5qdTb8GiDloM6M2M2pjf6tUYEk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2556466192</pqid></control><display><type>article</type><title>No shortcuts to SARS-CoV-2 antivirals</title><source>American Association for the Advancement of Science</source><creator>Edwards, Aled ; Hartung, Ingo V.</creator><creatorcontrib>Edwards, Aled ; Hartung, Ingo V.</creatorcontrib><description>Are many drug repurposers pursuing artifacts?
When the COVID-19 pandemic hit, there was massive investment into the discovery of new treatments. Given the urgent need, repurposing of approved or clinically pretested drugs appeared especially attractive because that strategy promised fast initiation of antiviral clinical studies. On page 541 of this issue, the study by Tummino
et al.
(
1
) raises concerns that many drug candidates that showed antiviral activity in hypothesis-free cellular screens and were then repurposed to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections may be scientific dead ends. Their study is a warning that even amid the pressure of a pandemic, scientific diligence is still essential.</description><identifier>ISSN: 0036-8075</identifier><identifier>EISSN: 1095-9203</identifier><identifier>DOI: 10.1126/science.abj9488</identifier><language>eng</language><publisher>Washington: The American Association for the Advancement of Science</publisher><subject>Antiviral activity ; Antiviral agents ; Coronaviruses ; COVID-19 ; Drug development ; Pandemics ; Severe acute respiratory syndrome ; Severe acute respiratory syndrome coronavirus 2 ; Viral diseases</subject><ispartof>Science (American Association for the Advancement of Science), 2021-07, Vol.373 (6554), p.488-489</ispartof><rights>Copyright © 2021, American Association for the Advancement of Science</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c371t-c52ce03297b39660ad9087e63f6eb14c51d5dcad1fbf58dc1078f74d62d6ab583</citedby><cites>FETCH-LOGICAL-c371t-c52ce03297b39660ad9087e63f6eb14c51d5dcad1fbf58dc1078f74d62d6ab583</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2884,2885,27924,27925</link.rule.ids></links><search><creatorcontrib>Edwards, Aled</creatorcontrib><creatorcontrib>Hartung, Ingo V.</creatorcontrib><title>No shortcuts to SARS-CoV-2 antivirals</title><title>Science (American Association for the Advancement of Science)</title><description>Are many drug repurposers pursuing artifacts?
When the COVID-19 pandemic hit, there was massive investment into the discovery of new treatments. Given the urgent need, repurposing of approved or clinically pretested drugs appeared especially attractive because that strategy promised fast initiation of antiviral clinical studies. On page 541 of this issue, the study by Tummino
et al.
(
1
) raises concerns that many drug candidates that showed antiviral activity in hypothesis-free cellular screens and were then repurposed to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections may be scientific dead ends. Their study is a warning that even amid the pressure of a pandemic, scientific diligence is still essential.</description><subject>Antiviral activity</subject><subject>Antiviral agents</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Drug development</subject><subject>Pandemics</subject><subject>Severe acute respiratory syndrome</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Viral diseases</subject><issn>0036-8075</issn><issn>1095-9203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpdkEtLAzEYRYMoWKtrtwMiuEmbL5m8lqX4gqJg1W3IJBmc0k5qMiP4753SWbm6i3u4XA5C10BmAFTMs2tC68LMVhtdKnWCJkA0x5oSdoomhDCBFZH8HF3kvCFk6DSboNuXWOSvmDrXd7noYrFevK3xMn5iWti2a36aZLf5Ep3VQ4SrMafo4-H-ffmEV6-Pz8vFCjsmocOOUxcIo1pWTAtBrNdEySBYLUIFpePguXfWQ13VXHkHRKpall5QL2zFFZuiu-PuPsXvPuTO7JrswnZr2xD7bCjnklJQAAN68w_dxD61w7sDJUohQNOBmh8pl2LOKdRmn5qdTb8GiDloM6M2M2pjf6tUYEk</recordid><startdate>20210730</startdate><enddate>20210730</enddate><creator>Edwards, Aled</creator><creator>Hartung, Ingo V.</creator><general>The American Association for the Advancement of Science</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QF</scope><scope>7QG</scope><scope>7QL</scope><scope>7QP</scope><scope>7QQ</scope><scope>7QR</scope><scope>7SC</scope><scope>7SE</scope><scope>7SN</scope><scope>7SP</scope><scope>7SR</scope><scope>7SS</scope><scope>7T7</scope><scope>7TA</scope><scope>7TB</scope><scope>7TK</scope><scope>7TM</scope><scope>7U5</scope><scope>7U9</scope><scope>8BQ</scope><scope>8FD</scope><scope>C1K</scope><scope>F28</scope><scope>FR3</scope><scope>H8D</scope><scope>H8G</scope><scope>H94</scope><scope>JG9</scope><scope>JQ2</scope><scope>K9.</scope><scope>KR7</scope><scope>L7M</scope><scope>L~C</scope><scope>L~D</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20210730</creationdate><title>No shortcuts to SARS-CoV-2 antivirals</title><author>Edwards, Aled ; Hartung, Ingo V.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-c52ce03297b39660ad9087e63f6eb14c51d5dcad1fbf58dc1078f74d62d6ab583</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antiviral activity</topic><topic>Antiviral agents</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Drug development</topic><topic>Pandemics</topic><topic>Severe acute respiratory syndrome</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Viral diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Edwards, Aled</creatorcontrib><creatorcontrib>Hartung, Ingo V.</creatorcontrib><collection>CrossRef</collection><collection>Aluminium Industry Abstracts</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Ceramic Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Computer and Information Systems Abstracts</collection><collection>Corrosion Abstracts</collection><collection>Ecology Abstracts</collection><collection>Electronics & Communications Abstracts</collection><collection>Engineered Materials Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Materials Business File</collection><collection>Mechanical & Transportation Engineering Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>METADEX</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ANTE: Abstracts in New Technology & Engineering</collection><collection>Engineering Research Database</collection><collection>Aerospace Database</collection><collection>Copper Technical Reference Library</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Materials Research Database</collection><collection>ProQuest Computer Science Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Civil Engineering Abstracts</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>Computer and Information Systems Abstracts Academic</collection><collection>Computer and Information Systems Abstracts Professional</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Science (American Association for the Advancement of Science)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Edwards, Aled</au><au>Hartung, Ingo V.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>No shortcuts to SARS-CoV-2 antivirals</atitle><jtitle>Science (American Association for the Advancement of Science)</jtitle><date>2021-07-30</date><risdate>2021</risdate><volume>373</volume><issue>6554</issue><spage>488</spage><epage>489</epage><pages>488-489</pages><issn>0036-8075</issn><eissn>1095-9203</eissn><abstract>Are many drug repurposers pursuing artifacts?
When the COVID-19 pandemic hit, there was massive investment into the discovery of new treatments. Given the urgent need, repurposing of approved or clinically pretested drugs appeared especially attractive because that strategy promised fast initiation of antiviral clinical studies. On page 541 of this issue, the study by Tummino
et al.
(
1
) raises concerns that many drug candidates that showed antiviral activity in hypothesis-free cellular screens and were then repurposed to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections may be scientific dead ends. Their study is a warning that even amid the pressure of a pandemic, scientific diligence is still essential.</abstract><cop>Washington</cop><pub>The American Association for the Advancement of Science</pub><doi>10.1126/science.abj9488</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0036-8075 |
| ispartof | Science (American Association for the Advancement of Science), 2021-07, Vol.373 (6554), p.488-489 |
| issn | 0036-8075 1095-9203 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2557221811 |
| source | American Association for the Advancement of Science |
| subjects | Antiviral activity Antiviral agents Coronaviruses COVID-19 Drug development Pandemics Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Viral diseases |
| title | No shortcuts to SARS-CoV-2 antivirals |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T08%3A00%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=No%20shortcuts%20to%20SARS-CoV-2%20antivirals&rft.jtitle=Science%20(American%20Association%20for%20the%20Advancement%20of%20Science)&rft.au=Edwards,%20Aled&rft.date=2021-07-30&rft.volume=373&rft.issue=6554&rft.spage=488&rft.epage=489&rft.pages=488-489&rft.issn=0036-8075&rft.eissn=1095-9203&rft_id=info:doi/10.1126/science.abj9488&rft_dat=%3Cproquest_cross%3E2557221811%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2556466192&rft_id=info:pmid/&rfr_iscdi=true |